SCG Cell Therapy acquires technology from A*STAR for novel cancer treatment

Singapore-based biotech SCG Cell Therapy has acquired the rights to human “induced pluripotent stem cell” (iPSC) technology, from the Agency for Science, Technology and Research (A*STAR)’s Accelerate Technologies (A*ccelerate).

The technology enables SCG to expand its cell therapy product portfolio and develop off-the-shelf cell-based cancer immunotherapy.

“iPSC is a technology that is derived from skin or blood cells that are reprogrammed back into an embryonic-like pluripotent state that can produce any type of human cell. This would allow for the production of a steady source of cells for all types of cell therapy,” said Dr Adrian Teo, principal investigator at A*STAR’s Institute of Molecular and Cell Biology (IMCB). SCG will use the iPSC technology to develop off-the-shelf natural killer (NK) cell therapy.